



Ain Shams University Faculty of Pharmacy

Department of Pharmaceutics and Industrial  
Pharmacy

# *Transdermal delivery of an antihypertensive drug*

by

*Rasha Ahmed Maher El sayed*

*Quality control special in National Organization for Drug Control and Research (NODCAR)*

*Bachelor degree of pharmaceutical science (2004)*

**Under the supervision of**

*Prof. Dr. Omaila A. Sammour*

*Professor of Pharmaceutics and Industrial  
Pharmacy Faculty of Pharmacy - Ain Shams  
University*

*Dr. Rihab Osman Ahmed*

*Associate Professor of Pharmaceutics and  
Industrial Pharmacy Faculty of Pharmacy - Ain  
Shams University*

*Dr. Abd El Moneim Abd El Ghany Swealem*

*Researcher at National Organization for Drug Control and Research  
(NODCAR)*

**(2017)**



فَالْحَمْدُ لِلَّهِ



## Acknowledgements

First and foremost thanks to God by the grace of whom this work was achieved.

Words not enough to express my profound gratitude to the ideal mother **Prof. Omaima Ahmed Amin Sammour**, Professor of Pharmaceutics and Industrial Pharmacy, faculty of pharmacy, Ain Shams University. I am indebted to her for the great help and effort. She devoted for the completion of the thesis, for her instructive supervision, valuable advices and moral support.

I would like to express my sincere gratitude and enormous appreciation to **Dr. Rihab Osman Ahmed**, Associate Professor of Pharmaceutics and industrial pharmacy, Ain Shams University. For careful and exigent reading of the thesis, critical comments, valuable advices, sincere encouragement, judicious suggestion and interpreting the results. She was never lacking in kindness and support.

My deepest appreciation to **the soul of Dr. Abd El Moneim Abd El Ghany Swealem**, Researcher at National Organization of Drug Control and Research (NODCAR) for his valuable support and his great efforts in planning, supervising the work, indispensable help and providing me with all facilities required to fulfill this work. Oh Allah ! Forgive him and have mercy on him and pardon him.

I am greatly thankful to **Dr. Dalia Mahmoud**, Assistant lecturer of Pharmaceutics and industrial pharmacy, Ain Shams University. For her technical advice and support.

I am greatly thankful to **Dr. Amira Hamed**, Assistant lecturer of Pharmaceutics and industrial pharmacy, Ain Shams University. For her technical advice and support.

My deep appreciation to all my colleagues in NODCAR, especially TLC lab for their valuable support.

## *Dedication*

*I dedicate this thesis to the soul of my mother, to my dearest father, who without his support in all my life this thesis wouldn't have appeared, to my dearest sister, brother and uncle.*

*Finally, I would like to express my infinite appreciation to my supportive Mohamed, my husband and my lovely children Sara, Marwan and Moataz for their support.*





## **List of contents**

<b>Topic</b>	<b>Page</b>
List of abbreviations	I
List of tables	IV
List of figures	VIII
Abstract	1
General introduction	5
Scope of work	12

### **Chapter I: Formulation and evaluation of polyvinyl alcohol/polyvinyl pyrrolidone composite matrix based films for lisinopril transdermal delivery.**

<b>1. Introduction.</b>	13
<b>2. Experimental.</b>	20
<b>2.1. Materials.</b>	
<b>2.2. Equipment.</b>	
<b>2.3. Methodology.</b>	21
2.3.1.1. Spectrophotometric assay of LSP.	21
2.3.1.1.1. Determination of wavelength of maximum absorption.	21
2.3.1.1.2. Construction of LSP calibration curve.	21
2.3.1.2. Determination of LSP partition coefficient in octanol/phosphate buffer system.	22
2.3.1.3. Drug excipients interactions.	22
2.3.1.3.1. Fourier transform-infrared (FT-IR) spectroscopy analysis.	23
2.3.1.3.2. Differential scanning calorimetry (DSC) analysis.	23
2.3.2. Preparation of PVA/PVP based transdermal films.	23

2.3.2.1. Preparation of plain PVA/PVP based films.	23
2.3.2.2. Preparation of LSP loaded PVA/PVP based films.	24
2.3.3. Evaluation of the prepared PVA/PVP based films.	27
2.3.3.1. Visual inspection.	27
2.3.3.2. Film thickness determination.	27
2.3.3.3. Weight determination.	27
2.3.3.4. Drug content determination.	27
2.3.3.5. Surface pH determination.	28
2.3.3.6. Water content determination.	28
2.3.3.7. Moisture uptake determination.	28
2.3.3.8. Mechanical properties determination.	29
2.3.3.9. <i>In vitro</i> release of LSP from PVA/PVP based films.	29
2.3.3.10. Kinetic analysis of <i>in vitro</i> release data.	30
2.3.3.11. <i>Ex vivo</i> permeation study.	32
2.3.3.12. DSC analysis of the final selected formula.	33
2.3.4. Stability of the selected LSP loaded PVA/PVP based transdermal film.	33
2.3.5. Statistical analysis.	34
<b>3. Results and Discussion.</b>	
3.1. Preformulation study.	35
3.1.1. Spectrophotometric assay of LSP.	35
3.1.2. Partition coefficient of LSP in octanol/phosphate buffer system.	37
3.1.3. Drug excipients interactions.	38
3.1.3.1. FT-IR analysis.	38
3.1.3.2. DSC analysis.	40
3.2. PVA/PVP matrix based films preparation.	41
3.3. Physical properties of LSP loaded PVA/PVP based films.	43

3.3.3. Drug content.	45
3.3.4. Surface pH.	45
3.3.5. Water content and moisture uptake of LSP-PVA/PVP based films.	46
3.3.6. Mechanical properties of LSP- PVA/PVP based films.	58
3.3.7. <i>In vitro</i> release of LSP.	66
3.3.8. Kinetic analysis of <i>in vitro</i> release of LSP from different formulae.	73
3.3.9. <i>Ex-vivo</i> permeation study.	74
3.4. DSC of LSP loaded PVA/PVP selected film (formula L6).	79
3.5. Stability of LSP loaded PVA/PVP selected film (formula L6).	80
<b>Conclusions.</b>	84

## **Chapter II: Formulation and evaluation of lisinopril loaded ethosomes incorporated in matrix films for transdermal delivery.**

<b>1. Introduction.</b>	86
<b>2. Experimental.</b>	92
<b>2.1. Materials.</b>	
<b>2.2. Equipment.</b>	
<b>2.3. Methodology.</b>	
2.3.1. Preparation of LSP loaded ethosome incorporated in PVA/PVP based transdermal film.	92
2.3.1.1. Preparation of LSP loaded ethosomes.	92
2.3.1.2. Experimental design used in the preparation of LSP loaded ethosomes.	94
2.3.1.3. Incorporation of ethosomes in PVA/PVP based transdermal film.	95
2.3.2. Characterization of LSP loaded ethosomes.	95

2.3.2.1. Vesicle size (VS) determination.	96
2.3.2.2. Entrapment efficiency determination.	96
2.3.2.3. Ethosomes surface charge determination.	97
2.3.2.4. Ethosomes morphology by transmission electron microscopy (TEM).	97
2.3.2.5. Physical stability of selected ethosomal formula.	97
2.3.3. Characterization of LSP loaded ethosome incorporated in PVA/PVP based film (LSP-ET/film).	98
2.3.3.1. Physico-chemical characterization of LSP-ET/film.	98
2.3.3.2. <i>In vitro</i> release of LSP from LSP-ET/film.	98
2.3.3.3. <i>Ex vivo</i> permeation study.	98
2.3.4. FT-IR analysis.	98
2.3.5. Physical stability of the selected LSP/ET-film after storage at 40±2°C and 75% RH for 6 months.	98
2.3.6. Statistical analysis	99
<b>3. Results and Discussion.</b>	
3.1. Vesicle size (VS) of different ethosomal formulae.	100
3.2. Entrapment efficiency (EE) of LSP in ethosomes.	107
3.3. Zeta potential.	113
3.4. Morphology of LSP-ethosomes (formula ET7).	119
3.5. Physical stability of LSP- ethosomes (formula ET7).	119
3.6. Morphology of LSP-ethosomes incorporated in transdermal film (LSP-ET/film).	121
3.7. Physico-chemical characteristics of LSP-ET/film compared to the conventional LSP film (L6).	122
3.8. <i>In vitro</i> release of LSP from ethosomal film.	123
3.9. <i>Ex-vivo</i> permeation study of ethosomal film.	125
3.10. FT-IR analysis of selected LSP-ET/film.	128

3.11. Stability of selected LSP-ET/film.	130
<b>Conclusions.</b>	134

### **Chapter III: *In vivo* evaluation of lisinopril transdermal films.**

<b>1. Introduction.</b>	136
<b>2. Experimental.</b>	139
<b>2.1. Materials.</b>	139
<b>2.2. Equipment.</b>	139
<b>2.3. Animals.</b>	140
<b>2.4. Pharmacokinetic study.</b>	140
2.4.1. HPLC assay of LSP in rabbit plasma.	140
2.4.1.1. Preparation of stock and working solutions.	140
2.4.1.2. Chromatographic conditions.	140
2.4.1.3. Plasma sample preparation.	141
2.4.1.4. Assay validation.	141
2.4.1.4.1. Selectivity.	141
2.4.1.4.2. Linearity and range.	142
2.4.1.4.3. Precision and accuracy.	142
2.4.1.4.4. Recovery.	143
2.4.1.4.5. Limit of detection (LOD).	143
2.4.1.4.6. Limit of quantification (LOQ).	143
2.4.2. Drug administration.	143
2.4.3. Collection of blood samples and sample preparation.	144
2.4.4. Determination of Pharmacokinetic parameters.	145
2.5. Histological study.	146
2.6. Statistical analysis.	146
<b>3. Results and Discussion</b>	
3.1. Chromatographic procedure.	147

3.2. Validation of the chromatographic method.	147
3.2.1. Selectivity.	147
3.2.2. Linearity and range.	149
3.2.3. Accuracy and precision.	149
3.2.4. Recovery.	150
3.2.5. Limit of detection (LOD).	151
3.2.6. Limit of quantification (LOQ).	151
3.3. Pharmacokinetic study.	151
3.4. Histological study.	158
<b>4. Conclusions.</b>	161
<b>General conclusion.</b>	162
<b>Summary.</b>	163
<b>References.</b>	168
<b>Arabic summary.</b>	

## **List of Abbreviations**

ACE	Angiotensin converting enzyme
ANOVA	Analysis of variance
AT1	Angiotensin II receptor type 1
AT2	Angiotensin II receptor type 2
AllRA	Angiotensin II receptor antagonist
AUC <sub>(0-∞)</sub>	Area under the plasma concentration curve from time zero to infinity
AUC <sub>(0-t)</sub>	Area under the plasma concentration curve from time zero to time t
BAV	Bioavailability
BGL	Blood glucose level
BP	Blood pressure
C <sub>max</sub>	Maximum peak plasma concentration.
CDR%	Cumulative drug release %
Conc	Concentration
CV%	Coefficient of variation percent
Da	Dalton
DMSO	Dimethyl sulfoxide
DSC	Differential scanning calorimetry
EC	Ethyl cellulose
EE%	Entrapment efficiency %
ET	Ethosomes
FDA	Food and Drug Administration
FT-IR	Fourier transform infrared spectrometry
GLY	Glycerol
h	Hour
HPMC	Hydroxy propyl methyl cellulose
HPLC	High performance liquid chromatography